Windward Bio develops monoclonal antibodies for advanced immunological diseases.
Windward Bio has raised $165.0M in total funding. The most recent round was Series B. The last funding was announced in May 2026.
Windward Bio's investors include RA Capital Management, Qiming Venture Partners, Janus Henderson Investors, Novo Holdings, Blue Owl.
Windward Bio is headquartered in Basel, Switzerland.
Windward Bio develops monoclonal antibodies for advanced immunological diseases.
Windward Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Windward Bio — Funding & Investors." VCBacked, May 4, 2026, https://www.vcbacked.co/company/windward-bio. Accessed August 14, 2026.
VCBacked. (2026). Windward Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/windward-bio
{{cite web |title=Windward Bio — Funding & Investors |url=https://www.vcbacked.co/company/windward-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated